###begin article-title 0
Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 145 146 145 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M</sub>
###xml 184 189 <span type="species:ncbi:9606">human</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
The atheroprotective effects of systemic delivery of either apolipoprotein A-I (wtApoA-I) or the naturally occurring mutant ApoA-I Milano (ApoA-IM) have been established in animal and human trials, but direct comparison studies evaluating the phenotype of ApoA-I or ApoAI-Milano knock-in mice or bone marrow transplantated animals with selectively ApoA-I or ApoAI-Milano transduced macrophages give conflicting results regarding the superior performance of either one. We therefore sought to compare the two forms of apoA-I using liver-directed somatic gene transfer in hypercholesterinemic mice - a model which is most adequately mimicking the clinical setting.
###end p 3
###begin title 4
Methods and results
###end title 4
###begin p 5
###xml 66 68 66 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 301 309 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">en face </italic>
###xml 434 436 434 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 33 37 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
Vectors based on AAV serotype 8 (AAV2.8) encoding wtApoA-I, ApoA-IM or green fluorescent protein (GFP) as control were constructed. LDL receptor deficient mice were fed a Western Diet. After 8 weeks the AAV vectors were injected, and 6 weeks later atherosclerotic lesion size was determined by aortic en face analysis. Expression of wtApoA-I reduced progression of atherosclerosis by 32% compared with control (p = 0.02) and of ApoA-IM by 24% (p = 0.04). There was no significant difference between the two forms of ApoA-I in inhibiting atherosclerosis progression.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 67 69 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 15 19 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
Liver-directed AAV2.8-mediated gene transfer of wtApoA-I and ApoA-IM each significantly reduced atherosclerosis progression to a similar extent.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 314 321 <span type="species:ncbi:9986">rabbits</span>
Apolipoprotein A-I (wtApoA-I) is the primary protein component of high density lipoproteins (HDL) [1] and like HDL cholesterol is inversely associated with atherosclerotic cardiovascular disease. Transgenic overexpression of wtApoA-I in liver substantially reduces progression of atherosclerosis in mice [2,3] and rabbits [4]. Furthermore, somatic gene transfer of wtApoA-I to liver using adenoviral vectors reduces progression [5,6] and induces regression [7] of atherosclerosis.
###end p 9
###begin p 10
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M</sub>
###xml 116 118 116 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 211 213 211 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 339 340 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 420 422 420 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 506 508 506 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 637 639 637 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 795 797 795 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1171 1173 1171 1173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 1247 1249 1247 1249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
###xml 1078 1086 <span type="species:ncbi:9606">patients</span>
###xml 1269 1274 <span type="species:ncbi:10090">mouse</span>
ApoA-I Milano (ApoA-IM) is a rare, naturally-occurring Arg173Cys point mutation in ApoA-I. Heterozygosity for ApoA-IM is associated with very low levels of HDL-C but no apparent increased risk of CHD [8]. ApoA-IM has been studied extensively with regard to effects on atherosclerosis, including infusion and genetic expression in animals [8,9] and even in a clinical trial of repeated intravenous infusion of an a ApoA-IM /phospholipid complexes in patients with CHD [10]. It has been suggested that ApoA-IM may be a gain-of-function mutation. Indeed, a recent study perfomed by Shan did show a superior atheroprotective effect of ApoA-IM compared to wtApoA-I transduced macrophages after bone marrow transplantation into ApoAI/ApoE double knock-out mice [11]. In contrast to that, female ApoA-IM knock-in animals are characterized by higher serum cholesterol levels and the development of larger atherosclerotic lesions compared to ApoA-I knock-in mice [12]. Due to the major differences in outcome of these studies and the lack of resemblance to the clinical setting in which patients with normal ApoA-I levels are treated with a systemically delivered ApoA-I or ApoA-IM mimetic compound, we wanted to elucidate the effects of wtApoA-I or ApoA-IM overexpression in a mouse model susceptible for atherosclerosis.
###end p 10
###begin p 11
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 217 219 217 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 190 195 <span type="species:ncbi:10090">mouse</span>
###xml 222 227 <span type="species:ncbi:10090">mouse</span>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 376 382 <span type="species:ncbi:9606">humans</span>
###xml 673 677 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 698 702 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
Adeno-associated viral (AAV) vectors have been shown to be capable of stable gene transfer and hepatic expression [13,14]. First-generation AAV vectors have been used to express wtApoA-I in mouse liver [15] and ApoA-IM in mouse muscle [16], but in both cases the levels of expression and plasma concentrations were extremely low compared with normal ApoA-I levels in mice and humans. Much greater expression can be obtained using vectors based on AAV serotype 8 [17]. A comparative study of AAV serotypes delivered intraportally showed that AAV8-based vectors achieved the highest levels of hepatic transgene expression and ranged from 16 to 110 times greater than that of AAV2; gene transfer from AAV2/7 was intermediate [18].
###end p 11
###begin p 12
###xml 89 91 89 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 261 263 261 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Therefore, in the current study we used AAV8-based vectors to express wtApoA-I and ApoA-IM in LDLreceptor deficient mice to test whether AAV-based overexpression of ApoA-I would reduce progression of atherosclerosis in this model and whether wtApoA-I and ApoA-IM differed in their effects on atherosclerosis.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Vectors
###end title 14
###begin p 15
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 366 370 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
Transgenes were human wtApoA-I and human apoA-I-Milano for the treatment groups and green fluorescent protein (eGFP) for the control group. The human ApoA-I-Milano gene was cloned via site directed mutagenesis of the wtApoA-I plasmid by PCR. Correct cloning was confirmed by sequencing and restriction digests. To produce AAV vectors encapsidated in an AAV8 capsid (AAV2.8), a pseudotyping strategy was performed as reported [18,19]. Vectors were purified using a standard cesium sedimentation method and titers were determined via TaqMan analysis using probes and primers targeting the BGH poly(A+) region of the vectors.
###end p 15
###begin title 16
Animal studies
###end title 16
###begin p 17
###xml 559 560 559 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M</sub>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">Mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 542 546 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 565 569 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 614 619 <span type="species:ncbi:10090">mouse</span>
LDL receptor deficient mice on C57BL/6 background (LDLR-/- mice) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained as a breeding colony. Mice were given unrestricted access to water. Male mice were put on western diet (0.15% cholesterol, 21% butterfat, DYETS, PA) for 8 weeks. After this time period, one group of animals was killed to determine the amount of atherosclerosis development at baseline. The remaining animals were randomly divided into 3 groups and injected intraportally with AAV2.8-TBG-wtApoA-I, AAV2.8-TBG-ApoA-IM, or AAV2.8-TBG-GFP at a dose 1 x 10e12 genome copies/mouse, tail vein injection. Animals remained on a western diet for 6 weeks thereafter and were then sacrificed. From all animals blood was obtained at least two times before and at designated time-points after gene transfer. At time of necropsy livers, hearts and aortas were harvested for further analysis. All studies were approved by the Institutional Animal Care and Use Committee of the Wistar Institute and the University of Pennsylvania.
###end p 17
###begin title 18
Serum analysis
###end title 18
###begin p 19
Blood samples were obtained from the retro-orbital plexus. For selected time points serum lipoproteins were separated by Fast Performance Liquid Chromatography (FPLC). The amount of plasma lipoproteins in the serum or the FPLC fractions was detected using an automated clinical chemistry analyzer (Alpha Wassermann, USA) or a manual assay according to the manufacturers instruction (Wako, USA). FPLC fractions #3;-#10 are corresponding to VLDL, #11;-#24 to IDL/LDL, and #25;-#40 to HDL.
###end p 19
###begin title 20
Western Blot
###end title 20
###begin p 21
###xml 175 179 <span type="species:ncbi:9925">goat</span>
###xml 185 190 <span type="species:ncbi:9606">human</span>
Serum (0.25 mul/well) or FPLC fractions (5 mul/well) were resolved on a 10% BisTris gel and transferred to PVDF membrane (Invitrogen, Carlsbad, California, USA). A polyclonal goat anti-human ApoA-I antibody (K45252G, Biodesign, Maine, USA) was used as primary antibody. Blots were developed using chemiluminescence.
###end p 21
###begin title 22
RealTime PCR
###end title 22
###begin p 23
###xml 85 91 <span type="species:ncbi:10090">murine</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
Gene expression was analyzed in liver samples using the "Assay on demand" System for murine and human apolipoprotein A-I from Applied Biosystems (Foster City, CA, USA) according to the manufacturer's instructions.
###end p 23
###begin title 24
Histological analysis
###end title 24
###begin p 25
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
For the quantification of the aortic plaques, the mouse aorta was carefully harvested and stained with Sudan IV (Sigma, Germany). Plaque size was determined using Phase 3 Imaging System (Media Cybernetics).
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
For the statistical analysis a T-Test was performed. Data are described as Mean +/- standard error of the mean (SEM). Differences with a p-value less than 0.5 were considered significant.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
ApoA-I expression and plasma lipids
###end title 29
###begin p 30
###xml 159 160 159 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M</sub>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 305 307 305 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 449 451 449 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Two weeks after injection, plasma levels of human ApoA-I were about 20 mg/dL in mice expressing wild-type wtApoA-I and about 30 mg/dl in mice expressing ApoA-IM, and they increased during the 6 weeks (Fig 1a and Table 1). Non-reduced SDS-PAGE of plasma revealed the presence of ApoA-I dimers in the ApoA-IM but not in the wtApoA-I treated or control groups (Fig 1b). At six weeks, upon necropsy, the hepatic mRNA abundance in the wtApoA-I and ApoA-IM groups were not significantly different (Fig 1c).
###end p 30
###begin p 31
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 177 182 <span type="species:ncbi:9606">Human</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 336 341 <span type="species:ncbi:10090">mouse</span>
###xml 674 680 <span type="species:ncbi:10090">murine</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
###xml 771 777 <span type="species:ncbi:10090">murine</span>
###xml 786 791 <span type="species:ncbi:9606">Human</span>
a) Serum levels of human apoA-I as evaluated at designated time points over the course of the study. There was no significant cross-reaction between mouse and the human apoA-I. Human apoA-I levels were increased in the groups treated with the human wtApoA-I (* p < 0.01) and ApoA-IM (# p < 0.01) compared to control b) Western Blots of mouse serum obtained 14 days after gene transfer under reduced and non-reduced conditions. In contrast to animals treated with the wtApoA-I or GFP-control vector there was under non-reduced conditions an additional band detected in the samples of the ApoA-IM animals corresponding with an apoA-I dimer. c) RealTime PCR from liver RNA for murine and human ApoA-I mRNA levels. There was no significant difference in expression levels of murine ApoA-I. Human ApoA-I was only detected in treated animals without a difference in mRNA levels between animals receiving the wild type or the mutant ApoA-I.
###end p 31
###begin p 32
Lipid profiles 6 weeks after gene transfer (14 weeks on Western Diet).
###end p 32
###begin p 33
** p < 0.01 vs. control, * p < 0.05 vs. control, # p < 0.05 vs. ApoA-I
###end p 33
###begin p 34
###xml 42 44 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 385 387 385 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 528 530 528 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
Expression of wild-type wtApoA-I or ApoA-IM had no significant effect on plasma total cholesterol, triglycerides, or phospholipids, but did reduce HDL-C levels (Table 1). Lipoprotein fractionation revealed no significant differences in the distribution of cholesterol among the three groups (Fig 2a). Western Blot analysis of the HDL fractions revealed both monomer and dimer of ApoA-IM and only monomer of wtApoA-I, as expected and showed no significantly different distribution pattern of the ApoA-I protein between the ApoA-IM and the wtApoA-I treated animals (Fig 2b).
###end p 34
###begin p 35
###xml 134 139 <span type="species:ncbi:9606">human</span>
Cholesterol and triglyceride analysis of FPLC fractions of serum samples 14 days after viral gene transfer. Western blot analysis for human apoA-I in the HDL fractions is shown below the cholesterol tracing.
###end p 35
###begin title 36
Atherosclerosis progression
###end title 36
###begin p 37
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 298 300 298 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 440 442 440 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
All three groups of mice injected with vector and followed for an additional 6 weeks had more atherosclerosis than mice analyzed at baseline (Fig. 3b). Animals injected with AAV8-wtApoA-I had 32% less aortic atherosclerosis than control animals (p = 0.02), whereas animals injected with AAV8-ApoA-IM had 24% less atherosclerosis than controls (p = 0.04) (Figs 3a and 3b). There was no statistical difference between the wild-type and ApoA-IM groups.
###end p 37
###begin p 38
###xml 111 119 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">en face </italic>
a) Representative aortas stained with Sudan IV. b) Determination of total aortic plaque area as evaluated with en face analysis. Compared with the control group, there was significantly less atherosclerosis animals treated with wtApoA-I (*p < 0.02) and ApoA-IM (# p < 0.04) but no significant difference between the wtApoA-I and ApoA-IM groups.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 374 376 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
In this manuscript, we report two new findings. First, we demonstrate using an AAV8-based vector to express wild-type human ApoA-I in the livers of atherosclerosis-prone mice that expression of ApoA-I is of sufficient extent and duration to significantly slow the progression of atherosclerosis. Second, in a direct comparison, we demonstrate that while expression of ApoA-IM also significantly slowed progression of atherosclerosis compared with controls, it did not differ significantly from wtApoA-I with regard to effects on atherosclerosis.
###end p 40
###begin p 41
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
While somatic gene transfer of wtApoA-I to liver using adenoviral vectors has been shown to reduce progression [5,6] and even induce regression [7] of atherosclerosis in mice, expression is transient and associated with substantial inflammation. In contrast, expression of wtApoA-I using these AAV8-based vectors was stable for 6 weeks and was associated with no increases in liver transaminases (data not shown). Importantly, expression and plasma levels of wtApoA-I were substantially higher than were seen using first generation AAV vectors [15]. This allowed us to reliably compare two different forms of ApoA-I, wild-type and Milano, with regard to their effects on atherosclerosis.
###end p 41
###begin p 42
###xml 118 120 118 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 273 275 273 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 446 448 446 448 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 526 528 526 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 728 730 728 730 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 863 864 863 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M</sub>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
###xml 803 811 <span type="species:ncbi:405018">cardinal</span>
Previous studies have already evaluated the effects of bone marrow transplantations with retrovirally ApoA-I or ApoA-IM transduced macrophages into hyperlipidemic ApoA-I/ApoE double knock out mice. In this experimental setting selective overexpression of wtApoA-I or ApoA-IM in macrophages significantly decreased aortic atherosclerosis as well as atherosclerotic plaque macrophage immunoreactivity, effects which were more pronounced with ApoA-IM compared to wtApoA-I [11]. In a second study the phenotype of ApoA-I or ApoA-IM knock-in mice on an atherosclerosis prone ApoB/ApoAII background was analyzed [12] with the finding of a less favorable lipid profile and a more pronounced atherosclerosis development in female ApoA-IM knock-in mice. These results provided by Shah and Rubin's groups provide cardinal differences in the comparison of wtApoA-I or ApoA-IM, which might be due to the selection of animal models.
###end p 42
###begin p 43
###xml 170 172 170 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 306 308 306 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 487 488 487 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M</sub>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
Nevertheless, both studies lack resemblance to the clinical setting in which patients with normal ApoA-I levels are treated with a systemically delivered ApoA-I or ApoA-IM mimetic compound. In our current report, we demonstrate that AAV8-mediated gene transfer with hepatic expression of wtApoA-I or ApoA-IM results in plasma levels of ApoA-I that are sufficient to significantly slow the development of atherosclerosis in mice. Interestingly we find that both forms, wtApoA-I and ApoA-IM, to be similar effective in their ability to retard atherosclerosis development in LDLr knockout mice.
###end p 43
###begin p 44
###xml 109 114 <span type="species:ncbi:9606">human</span>
Atheroprotection did occur despite a reduction in serum HDL levels in both treatment groups. This mimics the human situation, in which ApoA-I Milano carriers have reduced levels of HDL cholesterol, which paradoxically is associated with atheroprotection.
###end p 44
###begin p 45
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 477 492 <span type="species:ncbi:10090">transgenic mice</span>
The exact mechanism for the ApoA-I Milano induced decrease in HDL levels is not completely elucidated yet and the fact, that so far only heterozygotes for the mutation have been identified, who are producing wild-type and mutated ApoA-I, is making the answer more difficult. One of the hypotheses is that HDL-bound ApoA-I Milano leads to a faster catabolism of the HDL particles. This increase in cholesterol efflux from HDL-ApoA-I Milano particles was proven in ApoA-I Milano transgenic mice, which also display a decrease in HDL levels [20,21].
###end p 45
###begin p 46
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 333 339 <span type="species:ncbi:10090">murine</span>
The lipid data obtained in our animal model are therefore highly consistent with the human phenotype and the results from the transgenic animals. In our model HDL levels did also slightly decrease in those animals treated with wtApoA-I, even though to a lesser extent than in those treated with ApoA-I Milano. Hepatic mRNA levels of murine ApoA-I did not differ between control and wtApoA-I or ApoA-I Milano treated animals in our study, therefore a down-regulation of the endogenous gene due to the AAV gene transfer is unlikely.
###end p 46
###begin p 47
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
It is clear that the plasma HDL concentration itself is neither a surrogate for its functionality nor the kinetics of reverse cholesterol transport [22]. Since the main determinant of HDL levels is its clearance and the metabolism of the mature HDL particle is highly dependent on its composition, it is imaginable that also the wtApoA-I gene transfer did led to the production of HDL particles with a more favorable metabolism.
###end p 47
###begin p 48
###xml 50 56 <span type="species:ncbi:10090">murine</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 302 307 <span type="species:ncbi:9606">human</span>
###xml 312 318 <span type="species:ncbi:10090">murine</span>
Another assumption is, that essentially replacing murine apoA-I with human apoA-I in these studies resulted in a more functional HDL that inhibited atherosclerosis, and that wild-type and Milano did not differ in this effect. Indeed, there is substantial interest in the structural differences between human and murine apoA-I and it is plausible that they would differ in their anti-atherogenic effects. Further experiments have to be performed to further elucidate this phenomenon.
###end p 48
###begin p 49
###xml 316 318 316 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 477 479 477 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">M </sub>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
In conclusion, these results support the concept of using second generation AAV8-based vectors to achieve hepatic gene transfer and expression of transgenes that encode abundant plasma proteins (such as ApoA-I) for studies in animals. They also suggest that systemic wtApoA-I overexpression is as effective as ApoA-IM overexpression in reducing atherosclerosis progression in susceptible mice. Finally, they suggest that AAV8-mediated gene transfer of either wtApoA-I or ApoA-IM could be considered as an experimental clinical approach for the treatment of atherosclerosis.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
This study was supported by P01 HL59407 and P01 HL22633 from the National Heart Lung and Blood Institute.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
JS analyzed the tissues via RealTime PCR for gene expression, JMW and DJR participated in the study design and coordination and helped to critically review and draft the manuscript. All authors read and approved the final manuscript.
###end p 53
###begin title 54
Acknowledgements
###end title 54
###begin p 55
We thank the Vector and Animal Model Cores of the Gene Therapy Program for their professional help.
###end p 55
###begin article-title 56
New insights into the regulation of HDL metabolism and reverse cholesterol transport
###end article-title 56
###begin article-title 57
###xml 37 52 <span type="species:ncbi:10090">transgenic mice</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
###end article-title 57
###begin article-title 58
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
###end article-title 58
###begin article-title 59
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 97 104 <span type="species:ncbi:9986">rabbits</span>
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
###end article-title 59
###begin article-title 60
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models
###end article-title 60
###begin article-title 61
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia
###end article-title 61
###begin article-title 62
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
###end article-title 62
###begin article-title 63
Apolipoprotein A-I(Milano): current perspectives
###end article-title 63
###begin article-title 64
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice
###end article-title 64
###begin article-title 65
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial
###end article-title 65
###begin article-title 66
###xml 176 180 <span type="species:ncbi:10090">mice</span>
Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice
###end article-title 66
###begin article-title 67
###xml 115 120 <span type="species:ncbi:10090">mouse</span>
Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model
###end article-title 67
###begin article-title 68
###xml 41 47 <span type="species:ncbi:10090">murine</span>
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
###end article-title 68
###begin article-title 69
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor
###end article-title 69
###begin article-title 70
###xml 31 37 <span type="species:ncbi:10090">murine</span>
Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1
###end article-title 70
###begin article-title 71
AAV serotype-dependent apolipoprotein A-I Milano gene expression
###end article-title 71
###begin article-title 72
New recombinant serotypes of AAV vectors
###end article-title 72
###begin article-title 73
###xml 36 50 <span type="species:ncbi:9544">rhesus monkeys</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
###end article-title 73
###begin article-title 74
###xml 24 46 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 101 107 <span type="species:ncbi:10090">murine</span>
Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia
###end article-title 74
###begin article-title 75
###xml 78 93 <span type="species:ncbi:10090">transgenic mice</span>
Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice
###end article-title 75
###begin article-title 76
###xml 50 65 <span type="species:ncbi:10090">transgenic mice</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-I(Milano)
###end article-title 76
###begin article-title 77
Determinants of plasma HDL concentrations and reverse cholesterol transport
###end article-title 77

